Elranatamab vs. teclistamab: battle of the BCMA bispecifics in relapsed/refractory multiple myeloma
Expert Review of Hematology（2024）
Key words
Myeloma,bispecific antibodies,elranatamab,teclistamab,BCMA
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined